Table 3.
Clinical outcomes in CHD patients with T2DM during follow-up.
| Variables |
total |
Baseline HbA1c < 7 % |
Baseline HbA1c ≥ 7 % |
P value |
|---|---|---|---|---|
| n (%) | N = 6839 | N = 3023 | N = 3816 | |
| All-cause death | 229 (3.3) | 63 (2.1) | 166 (4.4) | <0.001 |
| Cardiac death | 165 (2.4) | 38 (1.3) | 127 (3.3) | <0.001 |
| Non-fatal MI | 117 (1.7) | 40 (1.3) | 77 (2.0) | 0.028 |
| Stroke | 193 (2.8) | 77 (2.5) | 116 (3.0) | 0.222 |
| Unplanned revascularization | 357 (5.2) | 138 (4.6) | 219 (5.7) | 0.030 |
| MACCE | 759 (11.1) | 271 (9.0) | 488 (12.8) | <0.001 |
CHD, coronary heart disease; T2DM, type2 diabetes mellitus; HbA1c, glycosylated hemoglobin; MI, myocardial infarction; MACCE, major adverse cardiac and cerebrovascular events.